Michael B Atkins Selected Research

Ligands

1/2023	Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
2/2022	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
1/2022	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
1/2018	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
10/2015	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
11/2014	Prognostic and predictive markers for the new immunotherapies.
10/2013	PD-1 as a potential target in cancer therapy.
6/2012	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael B Atkins Research Topics

Disease

137	Neoplasms (Cancer) 12/2023 - 03/2002
130	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 06/2002
109	Melanoma (Melanoma, Malignant) 04/2024 - 06/2002
26	Kidney Neoplasms (Kidney Cancer) 08/2023 - 04/2004
23	Disease Progression 04/2024 - 12/2009
20	Neoplasm Metastasis (Metastasis) 11/2023 - 01/2003
11	Brain Neoplasms (Brain Tumor) 11/2023 - 10/2008
8	Hypoxia (Hypoxemia) 07/2015 - 02/2005
7	Fatigue 10/2021 - 07/2003
6	Necrosis 01/2021 - 08/2007
6	Hypertension (High Blood Pressure) 12/2020 - 10/2009
6	Body Weight (Weight, Body) 01/2019 - 08/2007
4	COVID-19 03/2023 - 01/2020
4	Cardiotoxicity 12/2021 - 02/2009
4	Colitis 12/2021 - 04/2015
3	Fever (Fevers) 01/2022 - 07/2003
3	Uveal melanoma 10/2021 - 01/2019
3	Inflammation (Inflammations) 01/2021 - 05/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 06/2012
3	Exanthema (Rash) 01/2021 - 12/2009
3	Hypothyroidism 01/2018 - 07/2002
2	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 09/2008
2	Hypophysitis 12/2021 - 06/2015
2	Neurologic Manifestations (Neurological Manifestations) 11/2021 - 08/2018
2	Tics (Tic) 01/2021 - 01/2019
2	Pneumonia (Pneumonitis) 01/2020 - 01/2017
2	Infections 12/2019 - 05/2014

Drug/Important Bio-Agent (IBA)

39	Interleukin-2 (IL2)IBA 07/2015 - 06/2002
36	IpilimumabIBA 04/2024 - 11/2012
36	NivolumabIBA 04/2024 - 04/2014
36	Immune Checkpoint InhibitorsIBA 12/2023 - 02/2016
35	Sunitinib (Sutent)FDA Link 12/2023 - 09/2008
33	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2024 - 02/2005
27	Sorafenib (BAY 43-9006)FDA Link 01/2023 - 02/2006
23	pembrolizumabIBA 12/2023 - 11/2014
22	Biomarkers (Surrogate Marker)IBA 10/2022 - 06/2008
19	Axitinib (AG 013736)IBA 12/2023 - 05/2009
18	CytokinesIBA 01/2021 - 03/2002
17	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2024 - 01/2007
15	Bevacizumab (Avastin)FDA Link 02/2022 - 05/2009
9	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2023 - 06/2014
9	atezolizumabIBA 02/2022 - 11/2014
9	B7-H1 AntigenIBA 01/2022 - 02/2015
9	InterferonsIBA 03/2017 - 01/2005
8	Tyrosine Kinase InhibitorsIBA 02/2024 - 05/2006
8	LigandsIBA 01/2023 - 06/2012
8	Proteins (Proteins, Gene)FDA Link 10/2021 - 02/2005
8	TOR Serine-Threonine KinasesIBA 01/2016 - 03/2004
7	trametinibIBA 10/2023 - 06/2014
6	tivozanibIBA 01/2024 - 01/2020
6	dabrafenibIBA 10/2023 - 06/2014
6	Angiogenesis InhibitorsIBA 01/2021 - 01/2007
6	Phosphotransferases (Kinase)IBA 01/2021 - 03/2004
6	VemurafenibIBA 11/2020 - 02/2013
6	temsirolimus FDA Link 01/2016 - 03/2004
5	Programmed Cell Death 1 ReceptorIBA 01/2024 - 09/2016
5	SteroidsIBA 01/2022 - 01/2017
5	Monoclonal AntibodiesIBA 10/2019 - 07/2009
5	Dacarbazine (DIC)FDA LinkGeneric 06/2015 - 10/2002
4	AntibodiesIBA 01/2022 - 02/2016
4	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2021 - 07/2002
4	Alanine Transaminase (SGPT)IBA 12/2021 - 01/2018
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2021 - 05/2004
4	Peptides (Polypeptides)IBA 09/2017 - 05/2008
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2017 - 12/2009
4	Mitogen-Activated Protein KinasesIBA 09/2016 - 02/2006
4	Vinblastine (Vinblastine Sulfate)FDA Link 06/2015 - 10/2002
4	Cisplatin (Platino)FDA LinkGeneric 06/2015 - 10/2002
4	Interferon alpha-2 (Roferon-A)FDA Link 11/2014 - 01/2005
4	Carbonic Anhydrase IXIBA 11/2013 - 01/2009
4	Temozolomide (Temodar)FDA LinkGeneric 12/2009 - 10/2002
3	Interferon-gamma (Interferon, gamma)IBA 11/2023 - 07/2003
3	avelumabIBA 10/2022 - 01/2018
3	CaspasesIBA 10/2019 - 02/2006
3	human ALK1-Fc fusion proteinIBA 01/2019 - 07/2016
3	MTOR InhibitorsIBA 01/2014 - 01/2007
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2013 - 01/2009
3	VaccinesIBA 05/2008 - 03/2002
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2023 - 01/2017
2	EnzymesIBA 01/2022 - 03/2002
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2022
2	Everolimus FDA Link 01/2022 - 01/2021
2	Lipase (Acid Lipase)FDA Link 01/2021 - 01/2018
2	Gemcitabine FDA Link 01/2021 - 10/2015
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 04/2015
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2018
2	binimetinibIBA 11/2020 - 07/2015
2	cobimetinibIBA 11/2020 - 07/2015
2	encorafenibIBA 11/2020 - 07/2015
2	CTLA-4 AntigenIBA 10/2020 - 01/2020

Therapy/Procedure

132	Therapeutics 12/2023 - 06/2002
44	Immunotherapy 04/2024 - 03/2002
11	Drug Therapy (Chemotherapy) 01/2022 - 02/2005
7	Nephrectomy 02/2015 - 02/2005
7	Biological Therapy 11/2014 - 03/2002
6	Aftercare (After-Treatment) 08/2023 - 04/2014
3	Neoadjuvant Therapy 03/2023 - 11/2020
3	Injections 01/2021 - 06/2010
2	Radiotherapy 01/2021 - 10/2008
2	Craniotomy 01/2020 - 06/2015